Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Arch+Microbiol 2021 ; 203 (7): 4743-4749 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
An in vitro antiviral activity of iodine complexes against SARS-CoV-2 #MMPMID34136927
Altaf I; Nadeem MF; Hussain N; Nawaz M; Raza S; Shabbir MAB; Ashraf MA; Ali MA; Hassan S; Aziz MW; Matti N; Ashraf M; Ulla I; Fazal S; Rafique S; Mehmood A; Sardar N; Khan MT; Atique HMM; Ashraf S; Tahir Z; Mukhtar N; Yaqub T
Arch Microbiol 2021[Sep]; 203 (7): 4743-4749 PMID34136927show ga
Since the emergence of COVID-19 pandemic in China in late 2019, scientists are striving hard to explore non-toxic, viable anti-SARS-CoV-2 compounds or medicines. We determined In vitro anti-SARS-CoV-2 activity of oral formulations (syrup and capsule)of an Iodine-complex (Renessans). First, cell cytotoxicity of Renessans on the Vero cells was determined using MTT assay. Afterwards, the antiviral activity of Renessans was determined using viral inhibition assays and TCID(50). For this, nontoxic concentrations of the Renessans were used. The results showed that Renessans is nontoxic to the cells up to 50 microg/mL. At 1.5 microg/mL concentration, SARS-CoV-2 production was significantly reduced to 10(1.43) TCID(50) and 10(1.58) TCID(50) for the syrup and capsule, respectively, as compare to virus infected control cells 10(6.08) TCID(50) and we found the dose dependent inhibition of virus replication in the presence of Renessans. Renessans inhibited SARS-CoV-2 with an EC50 value of 0.425 microg/mL and 0.505 microg/mL for syrup and capsule, respectively. Furthermore, there was no virus detected at concentration of 50 microg/mL of Renessans. This study indicates that Renessans, containing iodine, have potential activity against SARS-CoV-2 which needs to be further investigated in human clinical trials.
free
free
free
Arch+Microbiol 2021 ; 203 (7): 4743-4749
